Diagnosis made clear through Presepsin testing
30 Jun 2026This brochure explores the clinical utility of Presepsin (sCD14-ST), a biomarker that rises early during bacterial infection and sepsis. Discover how Presepsin testing can support early diagnosis, ongoing treatment monitoring, and risk stratification, providing clinicians with valuable information alongside other diagnostic tools as part of a comprehensive sepsis management strategy.
The assay is available on AIA®-360 and AIA®-CL300 analyzers from Tosoh Bioscience - Diagnostics EMEA, delivering results in approximately 15–20 minutes for rapid clinical decision-making in emergency and critical care settings. The brochure also outlines the biological role of Presepsin in the innate immune response and its growing evidence base in sepsis diagnosis and prognosis.
Resource details
- Resource type: Product brochure
- Page count: 8
- Read time: 12 mins




